IMATINIB-DRLA (Imatinib)
imatinib 400 mg capsule, 30 · ORAL · PBS code 10933K
AUTHORITY_REQUIREDWhat it costs
AU$160.05 PBS-determined price per 30 units
Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.
- • First listed on the PBS: 2016-11-01.
- • Repeats: 5.
- • PBS program: GE.
Eligibility criteria for subsidised access
The following is the government's own wording from the PBS Schedule, shown unchanged.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Dermatofibrosarcoma protuberans
Initial treatment
The condition must be unresectable; or
The condition must be locally recurrent; or
The condition must be metastatic; AND
The treatment must not exceed a maximum dose of 800 mg per day.
Details of unresectable tumour or site of the local recurrence or site(s) of metastatic disease must be documented in the patient's medical records.
Sponsor: Dr Reddy's Laboratories (Australia) Pty Ltd ABN 16 120 092 408
Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.